Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
Age range
6 Months – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall survival
Timeframe: from 2012 to 2022 (data abdstraction period)
Time to laboratory value normalization
Timeframe: up to 24 weeks
Time to MAS laboratory remission
Timeframe: up to 24 weeks
Time to partial MAS laboratory remission
Timeframe: up to 24 weeks
Time to tapering of GCs
Timeframe: from index date to the last of 7 consecutive days receiving ≤1 mg/kg/day of prednisone (PDN) equivalent dose
Number of recurrent MAS episodes
Timeframe: from hospital discharge or 26-weeks from the index date, whichever occurs later, until the end of study data collection]
Administration of organ support care
Timeframe: from the index date until either the hospital discharge or 26 weeks, whichever occurs later
Characteristics of MAS treatment
Timeframe: up to 24 weeks
Clinical signs
Timeframe: at index date and 8 weeks after index date (allowed time window 6 to 12 weeks)